A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

Sponsor
Genentech, Inc.
Study ID
NCT00096967
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF therapy in Study AVF2107g, AVF2119g, or AVF2192g and who completed the parent study are eligible for inclusion in this trial. Subjects who have received placebo in Study AVF2107g or AVF2192g are also eligible.

Key Dates

First listed
Nov 18, 2004
Start date
Oct 31, 2002
Status verified
Mar 2014
Completion
Jul 31, 2004

Study Design

Enrollment
100 participants
Primary purpose
TREATMENT

Related Studies